The Prostate: A Target With Real Clinical Stakes

The prostate is a target with genuine clinical weight: benign prostatic hyperplasia affects nearly all men with age, and prostate cancer is among the most common male malignancies. That makes any compound aimed at prostate tissue interesting in principle — and absolutely not a self-research territory.

Prostamax applies the Khavinson bioregulator framework to that target, conceptually aiming at prostate cell gene expression. Members are emphatic: prostate symptoms require medical evaluation (including screening for cancer), and bioregulators are discussed here strictly as a research concept, never as a substitute for clinical care. The thread below holds that boundary firmly.